Despite the effectiveness of selective estrogen receptor modulators in estrogen receptor-positive breast cancer, resistance remains a challenge.343 Fulvestrant, the first FDA-approved selective estrogen receptor degrader, could overcome resistance associated with estrogen receptors modulators but is limited by poor oral bioavailability.344,345. The gene discussed is ESR1; the disease is breast cancer.